Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho » 12:33
06/05/20
06/05
12:33
06/05/20
12:33
BBIO

BridgeBio

$28.77 /

+1.04 (+3.75%)

, EIDX

Eidos Therapeutics

$49.03 /

+0.08 (+0.16%)

Mizuho analyst Salim Syed…

Mizuho analyst Salim Syed says that a key slide from the tafamidis presentation coming out of HFA indicates that more TTR stabilization reduces death risk and is better. He says the data for the 80 mg in the presentation "gets better over time," which is positive for BridgeBio (BBIO) and Eidos Therapeutics' (EIDX) AG10, and that every 10% PoS for AGIO ATTR-CM is worth $3 to the valuation. The analyst has a Buy rating and $51 price target on BridgeBio shares.

ShowHide Related Items >><<
EIDX Eidos Therapeutics
$49.03 /

+0.08 (+0.16%)

BBIO BridgeBio
$28.77 /

+1.04 (+3.75%)

BBIO BridgeBio
$28.77 /

+1.04 (+3.75%)

05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
04/13/20 H.C. Wainwright
BridgeBio initiated with a Buy at H.C. Wainwright
EIDX Eidos Therapeutics
$49.03 /

+0.08 (+0.16%)

05/14/20 JPMorgan
Eidos Therapeutics downgraded to Neutral on timeline delays at JPMorgan
05/14/20 JPMorgan
Eidos Therapeutics downgraded to Neutral from Overweight at JPMorgan
05/10/20 Piper Sandler
Piper Sandler bullish on Eidos, says AG10 opportunity remains very exciting
04/01/20 BofA
Eidos Therapeutics resumed with a Neutral at BofA
EIDX Eidos Therapeutics
$49.03 /

+0.08 (+0.16%)

BBIO BridgeBio
$28.77 /

+1.04 (+3.75%)

BBIO BridgeBio
$28.77 /

+1.04 (+3.75%)

BBIO BridgeBio
$28.77 /

+1.04 (+3.75%)

Over a month ago
Downgrade
Eidos Therapeutics downgraded to Neutral on timeline delays at JPMorgan » 06:16
05/14/20
05/14
06:16
05/14/20
06:16
EIDX

Eidos Therapeutics

$40.68 /

-0.61 (-1.48%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama downgraded Eidos Therapeutics to Neutral from Overweight with a price target of $50, down from $58. The analyst continues to believe AG10 has best in class stabilizer potential in the transthyretin amyloidosis space, but he sees the shares as a likely in line performer until timelines to data are more defined. The ATTRibute-CM trial is now expected to complete enrollment in the second half of 2021 due to COVID-19's impact, with data potentially shifted into the early-2022 timeframe, Rama tells investors in a research note.

ShowHide Related Items >><<
EIDX Eidos Therapeutics
$40.68 /

-0.61 (-1.48%)

EIDX Eidos Therapeutics
$40.68 /

-0.61 (-1.48%)

05/14/20 JPMorgan
Eidos Therapeutics downgraded to Neutral from Overweight at JPMorgan
05/10/20 Piper Sandler
Piper Sandler bullish on Eidos, says AG10 opportunity remains very exciting
04/01/20 BofA
Eidos Therapeutics resumed with a Neutral at BofA
02/20/20
Fly Intel: Top five analyst initiations
EIDX Eidos Therapeutics
$40.68 /

-0.61 (-1.48%)

Downgrade
Eidos Therapeutics downgraded to Neutral from Overweight at JPMorgan » 04:48
05/14/20
05/14
04:48
05/14/20
04:48
EIDX

Eidos Therapeutics

$40.68 /

-0.61 (-1.48%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama downgraded Eidos Therapeutics to Neutral from Overweight with a $50 price target.

ShowHide Related Items >><<
EIDX Eidos Therapeutics
$40.68 /

-0.61 (-1.48%)

EIDX Eidos Therapeutics
$40.68 /

-0.61 (-1.48%)

05/10/20 Piper Sandler
Piper Sandler bullish on Eidos, says AG10 opportunity remains very exciting
04/01/20 BofA
Eidos Therapeutics resumed with a Neutral at BofA
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Guggenheim
Eidos Therapeutics initiated with a Buy at Guggenheim
EIDX Eidos Therapeutics
$40.68 /

-0.61 (-1.48%)

Recommendations
Piper Sandler bullish on Eidos, says AG10 opportunity remains very exciting » 17:56
05/10/20
05/10
17:56
05/10/20
17:56
EIDX

Eidos Therapeutics

$43.00 /

+0.6 (+1.42%)

, PFE

Pfizer

$37.20 /

+0.24 (+0.65%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren has an Overweight rating and a $80 price target on Eidos Therapeutics (EIDX). The analyst notes that the impact of COVID-19 on timing of the ongoing Phase III ATTR-CM study is uncertain, as enrollment and site activation have both been delayed per management. Nevertheless, Eidos expects enrollment to be complete in the first half of 2021 and he expects topline results in 2022. Van Buren remains excited about the potential for AG10 to be a superior oral TTR stabilizer given the improved long-term outcomes relative to Pfizer's (PFE) Vyndaqel, and believes that peak sales opportunity for AG10 could be multi-billion.

ShowHide Related Items >><<
EIDX Eidos Therapeutics
$43.00 /

+0.6 (+1.42%)

04/01/20 BofA
Eidos Therapeutics resumed with a Neutral at BofA
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Guggenheim
Eidos Therapeutics initiated with a Buy at Guggenheim
02/18/20 Barclays
Eidos Therapeutics downgraded to Underweight from Equal Weight at Barclays
PFE Pfizer
$37.20 /

+0.24 (+0.65%)

04/29/20 Piper Sandler
Piper backs Overweight on Opko as BioReference starts COVID-19 antibody testing
04/28/20 SVB Leerink
SVB Leerink bullish on Zentalis, initiates with an Outperform
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/03/20 Canaccord
BioNTech price target raised to $60 from $22 at Canaccord
Hot Stocks
Eidos Therapeutics provides operational, clinical update amid COVID-19 pandemic » 16:36
05/08/20
05/08
16:36
05/08/20
16:36
EIDX

Eidos Therapeutics

$43.00 /

+0.6 (+1.42%)

Due to the impact of…

Due to the impact of COVID-19, the company has made several operational changes to ensure patient safety, comply with global health authorities' guidance, and maintain the integrity of its planned and ongoing clinical trials to evaluate the safety and efficacy of AG10 as a therapy for ATTR patients. These changes include: arranging alternatives to clinic visits for trial participants and study staff to minimize in-person interactions, facilitating home delivery of investigational medicine to enrolled participants where possible, identifying, and implementing, solutions to track and reduce missing data and protocol deviations. As COVID-19's long-term impact on study enrollment remains uncertain, the pandemic has unavoidably led to a slowdown in site activation and participant enrollment. The company cannot predict with certainty the timing of the completion of enrollment in ATTRibute-CM. The company currently expects enrollment of ATTRibute-CM to be completed in the first half of 2021 and plan to initiate our Phase 3 study of AG10 in ATTR-PN in the second half of 2020. The company has raised a total of $48.1M since December 2019, including $24.1M during the three months ended March 31, through "at-the-market" offerings under the 2019 registration statement on Form S-3. Eidos believes the company is well positioned with sufficient capital to fund through the receipt of Part A data from the Phase 3 ATTR-CM trial.

ShowHide Related Items >><<
EIDX Eidos Therapeutics
$43.00 /

+0.6 (+1.42%)

04/01/20 BofA
Eidos Therapeutics resumed with a Neutral at BofA
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Guggenheim
Eidos Therapeutics initiated with a Buy at Guggenheim
02/18/20 Barclays
Eidos Therapeutics downgraded to Underweight from Equal Weight at Barclays
Earnings
Eidos Therapeutics reports Q1 EPS (60c), consensus (53c) » 16:33
05/08/20
05/08
16:33
05/08/20
16:33
EIDX

Eidos Therapeutics

$43.00 /

+0.6 (+1.42%)

Cash and cash equivalents…

Cash and cash equivalents totaled $196.5M at March 31, compared with $191.2M at December 31, 2019. "We are living in unprecedented times as the impact of the COVID-19 pandemic spreads globally. We know ATTR patients are at great risk from COVID-19, and we are working with our investigators, clinical trial site administrators and patient advocacy leaders to put the health and welfare of our patients first," said Neil Kumar, CEO of Eidos. "We have made several operational changes to ensure their safety, critically ensuring that our investigational medicine is supplied without interruption, which in many cases has required direct delivery to study participants at their homes. We continue to believe that AG10 could be a best-in-class, convenient oral therapy for ATTR patients and remain committed to developing the drug as quickly and safely as possible."

ShowHide Related Items >><<
EIDX Eidos Therapeutics
$43.00 /

+0.6 (+1.42%)

04/01/20 BofA
Eidos Therapeutics resumed with a Neutral at BofA
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Guggenheim
Eidos Therapeutics initiated with a Buy at Guggenheim
02/18/20 Barclays
Eidos Therapeutics downgraded to Underweight from Equal Weight at Barclays
Conference/Events
Guggenheim healthcare analysts to hold an analyst/industry conference call » 14:25
04/23/20
04/23
14:25
04/23/20
14:25
MYOK

MyoKardia

$62.94 /

+1.18 (+1.91%)

, CYTK

Cytokinetics

$15.38 /

+0.32 (+2.12%)

, EIDX

Eidos Therapeutics

$48.46 /

+0.32 (+0.66%)

, ALNY

Alnylam

$142.17 /

+2.04 (+1.46%)

, AKCA

Akcea Therapeutics

$17.90 /

+0.91 (+5.36%)

, IONS

Ionis Pharmaceuticals

$56.74 /

+2.05 (+3.75%)

, AZN

AstraZeneca

$50.45 /

+0.09 (+0.18%)

, LLY

Eli Lilly

$159.43 /

+2.79 (+1.78%)

, JNJ

Johnson & Johnson

$155.43 /

+2.52 (+1.65%)

, AMGN

Amgen

$231.96 /

+2.62 (+1.14%)

, MRK

Merck

$80.87 /

+0.91 (+1.14%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Healthcare Analysts…

Healthcare Analysts discuss emerging therapies in heart failure and cardiomyopathies on an Analyst/Industry conference call to be held on April 23 at 3 pm.

ShowHide Related Items >><<
MYOK MyoKardia
$62.94 /

+1.18 (+1.91%)

03/31/20 Cantor Fitzgerald
MyoKardia's MAVERICK data keeps Cantor Fitzgerald 'positive'
02/11/20 Credit Suisse
MyoKardia price target raised to $82 from $77 at Credit Suisse
02/07/20 JPMorgan
MyoKardia shares can reach $100-$115 on positive data, says JPMorgan
01/27/20 Guggenheim
Guggenheim has high conviction in MyoKardia trial after cardiologist survey
CYTK Cytokinetics
$15.38 /

+0.32 (+2.12%)

04/17/20 Cantor Fitzgerald
Cytokinetics price target raised to $23 from $12 at Cantor Fitzgerald
04/09/20 Morgan Stanley
Cytokinetics upgraded to Overweight ahead of 'crucial year' at Morgan Stanley
04/09/20 Morgan Stanley
Cytokinetics upgraded to Overweight from Equal Weight at Morgan Stanley
03/04/20 H.C. Wainwright
H.C. Wainwright goes 'all in' on Cytokinetics into 'transformational' 2020
EIDX Eidos Therapeutics
$48.46 /

+0.32 (+0.66%)

04/01/20 BofA
Eidos Therapeutics resumed with a Neutral at BofA
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Guggenheim
Eidos Therapeutics initiated with a Buy at Guggenheim
02/18/20 Barclays
Eidos Therapeutics downgraded to Underweight from Equal Weight at Barclays
ALNY Alnylam
$142.17 /

+2.04 (+1.46%)

04/14/20 Cantor Fitzgerald
Alnylam price target raised to $202 from $195 at Cantor Fitzgerald
04/14/20 Nomura Instinet
Alnylam risks not absolved with Blackstone deal, says Nomura Instinet
04/13/20 Piper Sandler
Alnylam price target lowered to $142 from $147 at Piper Sandler
04/07/20 Piper Sandler
Alnylam's lumasiran sales could grow to $82M in 2021, says Piper Sandler
AKCA Akcea Therapeutics
$17.90 /

+0.91 (+5.36%)

01/22/20 Stifel
Akcea LICA data look 'solid,' as expected, says Stifel
10/08/19 BMO Capital
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
10/07/19 Stifel
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
10/07/19
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
IONS Ionis Pharmaceuticals
$56.74 /

+2.05 (+3.75%)

04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
03/05/20 Cantor Fitzgerald
Ionis study suspension has limited read to ongoing Phase 3, says Cantor
AZN AstraZeneca
$50.45 /

+0.09 (+0.18%)

04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
04/15/20 Morgan Stanley
AstraZeneca price target raised to 8,600 GBp from 8,250 GBp at Morgan Stanley
04/13/20 B. Riley FBR
AstraZeneca study halt has positive read-through to Fortress, says B. Riley FBR
02/28/20 Cowen
AstaZeneca pipeline leads to best European idea, says Cowen
LLY Eli Lilly
$159.43 /

+2.79 (+1.78%)

04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
04/20/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
04/09/20 Morgan Stanley
Morgan Stanley downgrades Eli Lilly to Equal Weight with premium near prior peak
JNJ Johnson & Johnson
$155.43 /

+2.52 (+1.65%)

04/22/20
Fly Intel: Top five analyst upgrades
04/22/20 BofA
Johnson & Johnson upgraded to Buy on defensiveness at BofA
04/22/20 BofA
Johnson & Johnson upgraded to Buy from Neutral at BofA
04/15/20 DA Davidson
Prestige Consumer price target raised to $47 from $43 at DA Davidson
AMGN Amgen
$231.96 /

+2.62 (+1.14%)

04/15/20 Guggenheim
Amgen initiated with a Neutral at Guggenheim
04/13/20 Citi
Sharp drop in chemo use negative for Amgen and Coherus, says Citi
03/31/20 Wolfe Research
Amgen initiated with a Peer Perform at Wolfe Research
03/30/20
Fly Intel: Top five analyst upgrades
MRK Merck
$80.87 /

+0.91 (+1.14%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
03/02/20 William Blair
Merck results revive fears about Seattle Genetics' Adcetris, says William Blair
02/27/20 Barclays
Merck initiated with an Overweight at Barclays
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
03/04/20 Deutsche Bank
Bayer upgraded to Buy from Hold at Deutsche Bank
Conference/Events
Guggenheim healthcare analysts to hold an analyst/industry conference call » 04:55
04/23/20
04/23
04:55
04/23/20
04:55
MYOK

MyoKardia

$61.76 /

-0.31 (-0.50%)

, CYTK

Cytokinetics

$15.06 /

+0.06 (+0.40%)

, EIDX

Eidos Therapeutics

$48.14 /

-0.06 (-0.12%)

, ALNY

Alnylam

$140.13 /

+2.17 (+1.57%)

, AKCA

Akcea Therapeutics

$16.99 /

+0.31 (+1.86%)

, IONS

Ionis Pharmaceuticals

$54.69 /

+1.36 (+2.55%)

, AZN

AstraZeneca

$50.36 /

+0.255 (+0.51%)

, LLY

Eli Lilly

$156.64 /

+3.85 (+2.52%)

, JNJ

Johnson & Johnson

$152.91 /

+3.14 (+2.10%)

, AMGN

Amgen

$229.34 /

-1.42 (-0.62%)

, MRK

Merck

$79.96 /

+1.43 (+1.82%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Healthcare Analysts…

Healthcare Analysts discuss emerging therapies in heart failure and cardiomyopathies on an Analyst/Industry conference call to be held on April 23 at 3 pm.

ShowHide Related Items >><<
MYOK MyoKardia
$61.76 /

-0.31 (-0.50%)

03/31/20 Cantor Fitzgerald
MyoKardia's MAVERICK data keeps Cantor Fitzgerald 'positive'
02/11/20 Credit Suisse
MyoKardia price target raised to $82 from $77 at Credit Suisse
02/07/20 JPMorgan
MyoKardia shares can reach $100-$115 on positive data, says JPMorgan
01/27/20 Guggenheim
Guggenheim has high conviction in MyoKardia trial after cardiologist survey
CYTK Cytokinetics
$15.06 /

+0.06 (+0.40%)

04/17/20 Cantor Fitzgerald
Cytokinetics price target raised to $23 from $12 at Cantor Fitzgerald
04/09/20 Morgan Stanley
Cytokinetics upgraded to Overweight ahead of 'crucial year' at Morgan Stanley
04/09/20 Morgan Stanley
Cytokinetics upgraded to Overweight from Equal Weight at Morgan Stanley
03/04/20 H.C. Wainwright
H.C. Wainwright goes 'all in' on Cytokinetics into 'transformational' 2020
EIDX Eidos Therapeutics
$48.14 /

-0.06 (-0.12%)

04/01/20 BofA
Eidos Therapeutics resumed with a Neutral at BofA
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Guggenheim
Eidos Therapeutics initiated with a Buy at Guggenheim
02/18/20 Barclays
Eidos Therapeutics downgraded to Underweight from Equal Weight at Barclays
ALNY Alnylam
$140.13 /

+2.17 (+1.57%)

04/14/20 Cantor Fitzgerald
Alnylam price target raised to $202 from $195 at Cantor Fitzgerald
04/14/20 Nomura Instinet
Alnylam risks not absolved with Blackstone deal, says Nomura Instinet
04/13/20 Piper Sandler
Alnylam price target lowered to $142 from $147 at Piper Sandler
04/07/20 Piper Sandler
Alnylam's lumasiran sales could grow to $82M in 2021, says Piper Sandler
AKCA Akcea Therapeutics
$16.99 /

+0.31 (+1.86%)

01/22/20 Stifel
Akcea LICA data look 'solid,' as expected, says Stifel
10/08/19 BMO Capital
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
10/07/19 Stifel
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
10/07/19
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
IONS Ionis Pharmaceuticals
$54.69 /

+1.36 (+2.55%)

04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
03/05/20 Cantor Fitzgerald
Ionis study suspension has limited read to ongoing Phase 3, says Cantor
AZN AstraZeneca
$50.36 /

+0.255 (+0.51%)

04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
04/15/20 Morgan Stanley
AstraZeneca price target raised to 8,600 GBp from 8,250 GBp at Morgan Stanley
04/13/20 B. Riley FBR
AstraZeneca study halt has positive read-through to Fortress, says B. Riley FBR
02/28/20 Cowen
AstaZeneca pipeline leads to best European idea, says Cowen
LLY Eli Lilly
$156.64 /

+3.85 (+2.52%)

04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
04/20/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
04/09/20 Morgan Stanley
Morgan Stanley downgrades Eli Lilly to Equal Weight with premium near prior peak
JNJ Johnson & Johnson
$152.91 /

+3.14 (+2.10%)

04/22/20
Fly Intel: Top five analyst upgrades
04/22/20 BofA
Johnson & Johnson upgraded to Buy on defensiveness at BofA
04/22/20 BofA
Johnson & Johnson upgraded to Buy from Neutral at BofA
04/15/20 DA Davidson
Prestige Consumer price target raised to $47 from $43 at DA Davidson
AMGN Amgen
$229.34 /

-1.42 (-0.62%)

04/15/20 Guggenheim
Amgen initiated with a Neutral at Guggenheim
04/13/20 Citi
Sharp drop in chemo use negative for Amgen and Coherus, says Citi
03/31/20 Wolfe Research
Amgen initiated with a Peer Perform at Wolfe Research
03/30/20
Fly Intel: Top five analyst upgrades
MRK Merck
$79.96 /

+1.43 (+1.82%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
03/02/20 William Blair
Merck results revive fears about Seattle Genetics' Adcetris, says William Blair
02/27/20 Barclays
Merck initiated with an Overweight at Barclays
BAYRY Bayer
$0.00 /

+ (+0.00%)

04/22/20 Morgan Stanley
Bayer price target lowered to EUR 83 from EUR 86 at Morgan Stanley
03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
03/04/20 Deutsche Bank
Bayer upgraded to Buy from Hold at Deutsche Bank
Conference/Events
Guggenheim healthcare analysts to hold an analyst/industry conference call » 10:09
04/21/20
04/21
10:09
04/21/20
10:09
MYOK

MyoKardia

$62.64 /

-3.31 (-5.02%)

, CYTK

Cytokinetics

$15.27 /

-0.23 (-1.48%)

, EIDX

Eidos Therapeutics

$49.44 /

+ (+0.00%)

, ALNY

Alnylam

$146.00 /

+1.41 (+0.98%)

, AKCA

Akcea Therapeutics

$16.54 /

-0.41 (-2.42%)

, IONS

Ionis Pharmaceuticals

$53.68 /

-1.87 (-3.37%)

, AZN

AstraZeneca

$50.40 /

-0.04 (-0.08%)

, LLY

Eli Lilly

$155.26 /

-2.61 (-1.65%)

, JNJ

Johnson & Johnson

$149.36 /

-2.49 (-1.64%)

, AMGN

Amgen

$233.94 /

-2.46 (-1.04%)

, MRK

Merck

$81.46 /

-1.6 (-1.93%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Healthcare Analysts…

Healthcare Analysts discuss emerging therapies in heart failure and cardiomyopathies on an Analyst/Industry conference call to be held on April 23 at 3 pm.

ShowHide Related Items >><<
MYOK MyoKardia
$62.64 /

-3.31 (-5.02%)

03/31/20 Cantor Fitzgerald
MyoKardia's MAVERICK data keeps Cantor Fitzgerald 'positive'
02/11/20 Credit Suisse
MyoKardia price target raised to $82 from $77 at Credit Suisse
02/07/20 JPMorgan
MyoKardia shares can reach $100-$115 on positive data, says JPMorgan
01/27/20 Guggenheim
Guggenheim has high conviction in MyoKardia trial after cardiologist survey
CYTK Cytokinetics
$15.27 /

-0.23 (-1.48%)

04/17/20 Cantor Fitzgerald
Cytokinetics price target raised to $23 from $12 at Cantor Fitzgerald
04/09/20 Morgan Stanley
Cytokinetics upgraded to Overweight ahead of 'crucial year' at Morgan Stanley
04/09/20 Morgan Stanley
Cytokinetics upgraded to Overweight from Equal Weight at Morgan Stanley
03/04/20 H.C. Wainwright
H.C. Wainwright goes 'all in' on Cytokinetics into 'transformational' 2020
EIDX Eidos Therapeutics
$49.44 /

+ (+0.00%)

04/01/20 BofA
Eidos Therapeutics resumed with a Neutral at BofA
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Guggenheim
Eidos Therapeutics initiated with a Buy at Guggenheim
02/18/20 Barclays
Eidos Therapeutics downgraded to Underweight from Equal Weight at Barclays
ALNY Alnylam
$146.00 /

+1.41 (+0.98%)

04/14/20 Cantor Fitzgerald
Alnylam price target raised to $202 from $195 at Cantor Fitzgerald
04/14/20 Nomura Instinet
Alnylam risks not absolved with Blackstone deal, says Nomura Instinet
04/13/20 Piper Sandler
Alnylam price target lowered to $142 from $147 at Piper Sandler
04/07/20 Piper Sandler
Alnylam's lumasiran sales could grow to $82M in 2021, says Piper Sandler
AKCA Akcea Therapeutics
$16.54 /

-0.41 (-2.42%)

01/22/20 Stifel
Akcea LICA data look 'solid,' as expected, says Stifel
10/08/19 BMO Capital
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
10/07/19 Stifel
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
10/07/19
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
IONS Ionis Pharmaceuticals
$53.68 /

-1.87 (-3.37%)

03/26/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target lowered to $56 from $65 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
03/05/20 Cantor Fitzgerald
Ionis study suspension has limited read to ongoing Phase 3, says Cantor
03/05/20 Wells Fargo
Ionis should be bought on misreading of trial suspension, says Wells Fargo
AZN AstraZeneca
$50.40 /

-0.04 (-0.08%)

04/16/20 JonesTrading
Gilead possible stake in Arcus positive for Surface, Infinity, says JonesTrading
04/15/20 Morgan Stanley
AstraZeneca price target raised to 8,600 GBp from 8,250 GBp at Morgan Stanley
04/13/20 B. Riley FBR
AstraZeneca study halt has positive read-through to Fortress, says B. Riley FBR
02/28/20 Cowen
AstaZeneca pipeline leads to best European idea, says Cowen
LLY Eli Lilly
$155.26 /

-2.61 (-1.65%)

04/21/20
Fly Intel: Top five analyst downgrades
04/21/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
04/20/20 UBS
Eli Lilly downgraded to Neutral from Buy at UBS
04/09/20 Morgan Stanley
Morgan Stanley downgrades Eli Lilly to Equal Weight with premium near prior peak
JNJ Johnson & Johnson
$149.36 /

-2.49 (-1.64%)

04/15/20 DA Davidson
Prestige Consumer price target raised to $47 from $43 at DA Davidson
04/15/20 Wells Fargo
Johnson & Johnson price target raised to $162 from $150 at Wells Fargo
04/15/20 Raymond James
Johnson & Johnson price target raised to $157 from $153 at Raymond James
04/15/20 Credit Suisse
Johnson & Johnson price target raised to $161 from $155 at Credit Suisse
AMGN Amgen
$233.94 /

-2.46 (-1.04%)

04/15/20 Guggenheim
Amgen initiated with a Neutral at Guggenheim
04/13/20 Citi
Sharp drop in chemo use negative for Amgen and Coherus, says Citi
03/31/20 Wolfe Research
Amgen initiated with a Peer Perform at Wolfe Research
03/30/20
Fly Intel: Top five analyst upgrades
MRK Merck
$81.46 /

-1.6 (-1.93%)

04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
03/02/20 William Blair
Merck results revive fears about Seattle Genetics' Adcetris, says William Blair
02/27/20 Barclays
Merck initiated with an Overweight at Barclays
BAYRY Bayer
$0.00 /

+ (+0.00%)

03/13/20 Goldman Sachs
Bayer price target lowered to EUR 76 from EUR 77 at Goldman Sachs
03/11/20 Deutsche Bank
Deutsche Bank names Bayer as 'Catalyst Call' buy idea
03/04/20 Deutsche Bank
Bayer upgraded to Buy from Hold at Deutsche Bank
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
Over a quarter ago
Initiation
Eidos Therapeutics resumed with a Neutral at BofA » 06:22
04/01/20
04/01
06:22
04/01/20
06:22
EIDX

Eidos Therapeutics

$48.86 /

-0.04 (-0.08%)

BofA analyst Geoff…

BofA analyst Geoff Meacham resumed coverage of Eidos Therapeutics with a Neutral rating and $51 price target. While AG10 has blockbuster potential with an expected launch in 2022 launch, the ATTR market is becoming more crowded with many effective therapies, Meacham tells investors in a research note. As such, the analyst's peak sales forecast of $2.4B is below the consensus of $3.0B.

ShowHide Related Items >><<
EIDX Eidos Therapeutics
$48.86 /

-0.04 (-0.08%)

02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Guggenheim
Eidos Therapeutics initiated with a Buy at Guggenheim
02/18/20 Barclays
Eidos Therapeutics downgraded to Underweight from Equal Weight at Barclays
02/18/20 Barclays
Eidos Therapeutics downgraded to Underweight from Equal Weight at Barclays

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.